Article Text

Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study
  1. Arthur Kavanaugh1,
  2. Roy M Fleischmann2,
  3. Paul Emery3,
  4. Hartmut Kupper4,
  5. Laura Redden5,
  6. Benoit Guerette5,
  7. Sourav Santra5,
  8. Josef S Smolen6
  1. 1Division of Rheumatology Allergy and Immunology, UCSD, San Diego, California, USA
  2. 2Division of Rheumatology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA
  3. 3Section of Musculoskeletal Disease, University of Leeds, Leeds, UK
  4. 4GPRD, Abbott Laboratories, Ludwigshafen, Germany
  5. 5GPRD, Abbott Laboratories, Abbott Park, Illinois, USA
  6. 6Division of Rheumatology, Medical University of Vienna, Vienna, Austria
  1. Correspondence to Arthur Kavanaugh, UCSD, UCSD, Rheumatology, Allergy, Immunology, 9500 Gilman Drive, MC 0943 La Jolla CA 92093-0943, USA; akavanaugh{at}ucsd.edu

Footnotes

  • Funding This study was funded by Abbott Laboratories.

  • Competing interests AK has provided expert advice to, and/or received research grants from Abbott, Amgen, Astra-Zeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche and UCB. RMF has received research grants and consulting fees or other remuneration from Abbott. PE has provided expert advice and undertaken trials for Abbott, Merck, Pfizer, UCB, Roche and BMS. HK, LR, BG and SS are Abbott employees and may hold stock or options. JSS has received research grants and/or consulting fees or other remuneration from Abbott, Amgen, Astra-Zeneca, BMS, Celgene Centocor-Janssen, Glaxo, Lilly, Pfizer (Wyeth), MSD (Schering-Plough), Novo-Nordisk, Roche, Sandoz and UCB.

  • Ethics approval A central institutional review board or independent ethics committee approved the study at each site.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

View Full Text

Statistics from Altmetric.com

Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:

    • Web Only Data - This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
    • Web Only Data - This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Footnotes

  • Funding This study was funded by Abbott Laboratories.

  • Competing interests AK has provided expert advice to, and/or received research grants from Abbott, Amgen, Astra-Zeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche and UCB. RMF has received research grants and consulting fees or other remuneration from Abbott. PE has provided expert advice and undertaken trials for Abbott, Merck, Pfizer, UCB, Roche and BMS. HK, LR, BG and SS are Abbott employees and may hold stock or options. JSS has received research grants and/or consulting fees or other remuneration from Abbott, Amgen, Astra-Zeneca, BMS, Celgene Centocor-Janssen, Glaxo, Lilly, Pfizer (Wyeth), MSD (Schering-Plough), Novo-Nordisk, Roche, Sandoz and UCB.

  • Ethics approval A central institutional review board or independent ethics committee approved the study at each site.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.